A new drug for recurrent glioblastoma vs standard care
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new targeted drug, TLX101-Tx, added to standard care for people with glioblastoma that has come back after initial treatment. It aims to see if the combination helps control the tumor better than standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of brain cancer called glioblastoma (IDH-wildtype).
- Your tumor must have come back after your first treatment (surgery, radiation, or chemo).
- You need to be at least 18 years old.
- You should be in fairly good health, able to care for yourself (ECOG score 0-2 or Karnofsky score 70 or higher).
- You must have a special PET scan showing the tumor is active and can be measured.
- If you have had steroid medicine for brain swelling, the dose must be stable for at least 7 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This trial combines laser heat therapy (LITT) with the chemotherapy drug lomustine (CCNU) for people whose glioblastoma has returned. It aims to see if the combination is safe and effective.
Hear when a new Neoplastic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.